Literature DB >> 22552984

Confronting "confounding by health system use" in Medicare Part D: comparative effectiveness of propensity score approaches to confounding adjustment.

Jennifer M Polinski1, Sebastian Schneeweiss, Robert J Glynn, Joyce Lii, Jeremy A Rassen.   

Abstract

PURPOSE: Under Medicare Part D, patient characteristics influence plan choice, which in turn influences Part D coverage gap entry. We compared predefined propensity score (PS) and high-dimensional propensity score (hdPS) approaches to address such "confounding by health system use" in assessing whether coverage gap entry is associated with cardiovascular events or death.
METHODS: We followed 243,079 Medicare patients aged 65+ years with linked prescription, medical, and plan-specific data in 2005-2007. Patients reached the coverage gap and were followed until an event or year's end. Exposed patients were responsible for drug costs in the gap; unexposed patients (patients with non-Part D drug insurance and Part D patients receiving a low-income subsidy) received financial assistance. Exposed patients were 1:1 PS-matched or hdPS-matched to unexposed patients. The PS model included 52 predefined covariates; the hdPS model added 400 empirically identified covariates. Hazard ratios for death and any of five cardiovascular outcomes were compared. In sensitivity analyses, we explored residual confounding using only low-income subsidy patients in the unexposed group.
RESULTS: In unadjusted analyses, exposed patients had no greater hazard of death (HR = 1.00; 95%CI, 0.84-1.20) or other outcomes. PS-matched (HR = 1.29; 0.99-1.66) and hdPS-matched (HR = 1.11; 0.86-1.42) analyses showed elevated but non-significant hazards of death. In sensitivity analyses, the PS analysis showed a protective effect (HR = 0.78; 0.61-0.98), whereas the hdPS analysis (HR = 1.06; 0.82-1.37) confirmed the main hdPS findings.
CONCLUSION: Although the PS-matched analysis suggested elevated but non-significant hazards of death among patients with no financial assistance during the gap, the hdPS analysis produced lower estimates that were stable across sensitivity analyses.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22552984      PMCID: PMC3367305          DOI: 10.1002/pds.3250

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  24 in total

1.  Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data.

Authors:  S Schneeweiss; J D Seeger; M Maclure; P S Wang; J Avorn; R J Glynn
Journal:  Am J Epidemiol       Date:  2001-11-01       Impact factor: 4.897

Review 2.  A review of uses of health care utilization databases for epidemiologic research on therapeutics.

Authors:  Sebastian Schneeweiss; Jerry Avorn
Journal:  J Clin Epidemiol       Date:  2005-04       Impact factor: 6.437

3.  Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect.

Authors:  Tobias Kurth; Alexander M Walker; Robert J Glynn; K Arnold Chan; J Michael Gaziano; Klaus Berger; James M Robins
Journal:  Am J Epidemiol       Date:  2005-12-21       Impact factor: 4.897

Review 4.  Indications for propensity scores and review of their use in pharmacoepidemiology.

Authors:  Robert J Glynn; Sebastian Schneeweiss; Til Stürmer
Journal:  Basic Clin Pharmacol Toxicol       Date:  2006-03       Impact factor: 4.080

5.  Variable selection for propensity score models.

Authors:  M Alan Brookhart; Sebastian Schneeweiss; Kenneth J Rothman; Robert J Glynn; Jerry Avorn; Til Stürmer
Journal:  Am J Epidemiol       Date:  2006-04-19       Impact factor: 4.897

Review 6.  A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods.

Authors:  Til Stürmer; Manisha Joshi; Robert J Glynn; Jerry Avorn; Kenneth J Rothman; Sebastian Schneeweiss
Journal:  J Clin Epidemiol       Date:  2005-10-13       Impact factor: 6.437

7.  Matching using estimated propensity scores: relating theory to practice.

Authors:  D B Rubin; N Thomas
Journal:  Biometrics       Date:  1996-03       Impact factor: 2.571

8.  Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus.

Authors:  P Michael Ho; John S Rumsfeld; Frederick A Masoudi; David L McClure; Mary E Plomondon; John F Steiner; David J Magid
Journal:  Arch Intern Med       Date:  2006-09-25

9.  A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results.

Authors: 
Journal:  JAMA       Date:  1983-11-25       Impact factor: 56.272

10.  Changes in drug utilization during a gap in insurance coverage: an examination of the medicare Part D coverage gap.

Authors:  Jennifer M Polinski; William H Shrank; Haiden A Huskamp; Robert J Glynn; Joshua N Liberman; Sebastian Schneeweiss
Journal:  PLoS Med       Date:  2011-08-16       Impact factor: 11.069

View more
  4 in total

1.  On the role of marginal confounder prevalence - implications for the high-dimensional propensity score algorithm.

Authors:  Tibor Schuster; Menglan Pang; Robert W Platt
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-04-10       Impact factor: 2.890

2.  Head to head comparison of the propensity score and the high-dimensional propensity score matching methods.

Authors:  Jason R Guertin; Elham Rahme; Colin R Dormuth; Jacques LeLorier
Journal:  BMC Med Res Methodol       Date:  2016-02-19       Impact factor: 4.615

3.  Performance of the high-dimensional propensity score in adjusting for unmeasured confounders.

Authors:  Jason R Guertin; Elham Rahme; Jacques LeLorier
Journal:  Eur J Clin Pharmacol       Date:  2016-08-30       Impact factor: 2.953

Review 4.  Automated data-adaptive analytics for electronic healthcare data to study causal treatment effects.

Authors:  Sebastian Schneeweiss
Journal:  Clin Epidemiol       Date:  2018-07-06       Impact factor: 4.790

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.